Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972848 | 0.73 | ALDH1A1 (0.41) | ALDH1A1MAPK1CYP1A2LMNAMAPT | |
| SCHEMBL15602711 | 0.72 | — | — | |
| SCHEMBL5047733 | 0.63 | ALDH1A1 (0.47) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| SCHEMBL195477 | 0.61 | ALDH1A1 (0.53) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL2548048 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL164 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL29008551 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL4002609 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL1358618 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 | |
| Biphenyl SCHEMBL28890607 | 0.61 | ALDH1A1 (1.00) | ALDH1A1MAPK1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5312707-A | Compositions for images | RICOH COMPANY, LTD. (JP) | 1994-05-17 | — | — | US | claimed |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240190883-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240190885-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240116845-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NUCMITO PHARMACEUTICALS CO LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | SHANGHAI RUOTUO BIOSCIENCES CO LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | disclosed |
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-20030224222-A1 | Aromatic polysulfone resin and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-12-04 | — | — | US | disclosed |
| EP-0620818-A1 | ARYL KETONES AS TESTOSTERONE 5$g(a)-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5312707-A | Compositions for images | RICOH COMPANY, LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| WO-1993013099-A1 | ARYL KETONES AS TESTOSTERONE 5α-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | ALDH1A1 189/4885MAPK1 3901/4885NPC1 185/4885 |
| US-20240190885-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, NRAS, APC | ALDH1A1 3269/4885MAPK1 634/4885NPC1 1634/4885 |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ALDH1A1 3564/4885MAPK1 496/4885NPC1 578/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ALDH1A1 3542/4885MAPK1 502/4885NPC1 571/4885 |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE12 | ALDH1A1 322/4885MAPK1 3060/4885NPC1 2635/4885 |
| US-20240066138-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | FCGR1A, FCGRT, FCGR2A | ALDH1A1 315/4885MAPK1 1555/4885NPC1 159/4885 |
| US-20240116845-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | MMP1, IDO1, COL1A1 | ALDH1A1 120/4885MAPK1 3381/4885NPC1 54/4885 |
| US-20240190883-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, NRAS, APC | ALDH1A1 3188/4885MAPK1 622/4885NPC1 1691/4885 |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | ALDH1A1 314/4885MAPK1 1860/4885NPC1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.